

GLAXOSMITHKLINE PLC
Form 6-K
April 19, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 19 April 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global
Manufacturing & Supply
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017.
 - c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|-----------|
| £16.4042 | 403.744 |
 - d) Aggregated information n/a (single transaction)
 - d) Aggregated volume Price
 - e) Date of the transaction 2017-04-18
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr L Debruyne
 - b) Position/status President, Global Vaccines
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13

| | | |
|---|--|-----------|
| | April 2017. | |
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £16.4042 | 1,079.517 |
| d) Aggregated information | n/a (single transaction) | |
| e) Date of the transaction | 2017-04-18 | |
| f) Place of the transaction | London Stock Exchange (XLON) | |
| 1. Details of PDMR/person closely associated with them ('PCA') | | |
| a) Name | Mr S Dingemans | |
| b) Position/status | Chief Financial Officer | |
| c) Initial notification/ amendment | Initial notification | |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) Name | GlaxoSmithKline plc | |
| b) LEI | 5493000HZTVUYLO1D793 | |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | |
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') | |
| b) Nature of the transaction | ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017. | |
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £16.4042 | 871.935 |
| d) Aggregated information | n/a (single transaction) | |
| e) Date of the transaction | 2017-04-18 | |
| f) Place of the transaction | London Stock Exchange (XLON) | |
| 1. Details of PDMR/person closely associated with them ('PCA') | | |
| a) Name | Mr S A Hussain | |
| b) Position/status | President, Global Pharmaceuticals | |
| c) Initial notification/ amendment | Initial notification | |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) Name | GlaxoSmithKline plc | |
| b) LEI | 5493000HZTVUYLO1D793 | |
| 3. | | |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') |
| b) Nature of the transaction | ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £16.4042 1,375.318 |
| d) Aggregated information | n/a (single transaction) |
| e) Date of the transaction | 2017-04-18 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|---------------------------------------|------------------------|
| a) Name | Mr D S Redfern |
| b) Position/status | Chief Strategy Officer |
| c) Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') |
| b) Nature of the transaction | ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £16.4042 1,471.854 |
| d) Aggregated information | n/a (single transaction) |
| e) Date of the transaction | 2017-04-18 |
| f) Place of the transaction | London Stock Exchange (XLON) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms C Thomas
 - b) Position/status SVP, HR
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017.
 - c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|-----------|
| £16.4042 | 478.351 |
 - d) Aggregated information n/a (single transaction)
 - e) Aggregated volume Price
 - f) Date of the transaction 2017-04-18
 - g) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr P C Thomson
 - b) Position/status President, Global Affairs
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13

| | | |
|---|--|-----------|
| | April 2017. | |
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £16.4042 | 690.515 |
| Aggregated information | n/a (single transaction) | |
| d) Aggregated volume Price | | |
| e) Date of the transaction | 2017-04-18 | |
| f) Place of the transaction | London Stock Exchange (XLON) | |
| 1. Details of PDMR/person closely associated with them ('PCA') | | |
| a) Name | Dr P J T Vallance | |
| b) Position/status | President, R&D | |
| c) Initial notification/ amendment | Initial notification | |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) Name | GlaxoSmithKline plc | |
| b) LEI | 5493000HZTVUYLO1D793 | |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | |
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') | |
| | ISIN: GB0009252882 | |
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017. | |
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £16.4042 | 2,767.208 |
| Aggregated information | n/a (single transaction) | |
| d) Aggregated volume Price | | |
| e) Date of the transaction | 2017-04-18 | |
| f) Place of the transaction | London Stock Exchange (XLON) | |
| 1. Details of PDMR/person closely associated with them ('PCA') | | |
| a) Name | Mrs K Thomson | |
| b) Position/status | PCA of Mr P C Thomson (President, Global Affairs) | |
| c) Initial notification/ amendment | Initial notification | |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) Name | GlaxoSmithKline plc | |
| b) LEI | 5493000HZTVUYLO1D793 | |
| 3. | | |

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') |
| b) Nature of the transaction | ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £16.4042 130.423 |
| d) Aggregated information | n/a (single transaction) |
| e) Date of the transaction | 2017-04-18 |
| f) Place of the transaction | London Stock Exchange (XLON) |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 19, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc